Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Fill-finish Pharmaceutical Contract Manufacturing Market

Fill-finish Pharmaceutical Contract Manufacturing Market Share

Report ID: GMI9281
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Fill-finish Pharmaceutical Contract Manufacturing Market Share

The fill-finish pharmaceutical contract manufacturing industry is characterized by a diverse mix of players, ranging from multinational corporations to small companies. Large multinational CMOs, such as Boehringer Ingelheim International GmbH, Eurofins Scientific, and Novartis AG dominated a significant portion of the market share. These companies offer comprehensive services, leveraging their global footprint, extensive infrastructure, and diversified service offerings to cater to a wide range of client needs.

Fill-finish Pharmaceutical Contract Manufacturing Market Companies

Prominent players operating in the fill-finish pharmaceutical contract manufacturing industry include:

Boehringer Ingelheim International GmbH
Catalent Inc
Eurofins Scientific
Fresenius Kabi Contract Manufacturing
MabPlex International Co. Ltd.
Novartis AG
Recipharm AB
Societal CDMO
Simtra BioPharma Solutions (Baxter International Inc.)
Symbiosis Pharmaceutical Services

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size for fill-finish pharmaceutical contract manufacturing was valued at USD 7.7 billion in 2023 and is anticipated to grow at 6.2% CAGR between 2024

The vials segment in the fill-finish pharmaceutical contract manufacturing market accounted for USD 4.1 billion in 2023, due to their durability, sterility, and ease of use.

North America fill-finish pharmaceutical contract manufacturing market is anticipated to grow at 5.9% CAGR from 2024 to 2032, attributed to the advanced healthcare infrastructure and a strong regulatory framework.

Boehringer Ingelheim International GmbH, Catalent Inc, Eurofins Scientific, Fresenius Kabi Contract Manufacturing, MabPlex International Co. Ltd., Novartis AG, Recipharm AB, Societal CDMO, Simtra BioPharma Solutions (Baxter International Inc.) and Symbiosis Pharmaceutical Services